[HTML] mdpi.com

[HTML][HTML] Empagliflozin attenuates vascular calcification in mice with chronic kidney disease by regulating the NFR2/HO-1 anti-inflammatory pathway through AMPK …

CW Lu, CJ Lee, YJ Hsieh, BG Hsu - International Journal of Molecular …, 2023 - mdpi.com
Vascular calcification (VC) is associated with increased cardiovascular risks in patients with
chronic kidney disease (CKD). Sodium-glucose cotransporter 2 inhibitors, such as …
被引用次数：12 相关文章

Empagliflozin Attenuates Vascular Calcification in Mice with Chronic Kidney Disease by Regulating the NFR2/HO-1 Anti-Inflammatory Pathway through AMPK …

CW Lu, CJ Lee, YJ Hsieh, BG Hsu - International Journal of …, 2023 - europepmc.org
Vascular calcification (VC) is associated with increased cardiovascular risks in patients with
chronic kidney disease (CKD). Sodium-glucose cotransporter 2 inhibitors, such as …
[HTML] nih.gov

[HTML][HTML] Empagliflozin Attenuates Vascular Calcification in Mice with Chronic Kidney Disease by Regulating the NFR2/HO-1 Anti-Inflammatory Pathway through AMPK …

CW Lu, CJ Lee, YJ Hsieh, BG Hsu - International Journal of …, 2023 - ncbi.nlm.nih.gov
Vascular calcification (VC) is associated with increased cardiovascular risks in patients with
chronic kidney disease (CKD). Sodium-glucose cotransporter 2 inhibitors, such as …

Empagliflozin Attenuates Vascular Calcification in Mice with Chronic Kidney Disease by Regulating the NFR2/HO-1 Anti-Inflammatory Pathway through AMPK …

CW Lu, CJ Lee, YJ Hsieh, BG Hsu - 2023 - preprints.org
Vascular calcification (VC) is associated with increased cardiovascular risks in patients with
chronic kidney disease (CKD). Sodium-glucose cotransporter 2 inhibitors, like empagliflozin …

Empagliflozin Attenuates Vascular Calcification in Mice with Chronic Kidney Disease by Regulating the NFR2/HO-1 Anti-Inflammatory Pathway through AMPK …

CW Lu, CJ Lee, YJ Hsieh… - International journal of …, 2023 - pubmed.ncbi.nlm.nih.gov
Vascular calcification (VC) is associated with increased cardiovascular risks in patients with
chronic kidney disease (CKD). Sodium-glucose cotransporter 2 inhibitors, such as …
[PDF] semanticscholar.org

[PDF][PDF] Empagliflozin Attenuates Vascular Calcification in Mice with Chronic Kidney Disease by Regulating the NFR2/HO-1 Anti-Inflammatory Pathway through AMPK …

CW Lu, CJ Lee, YJ Hsieh, BG Hsu - Int. J. Mol. Sci - pdfs.semanticscholar.org
Vascular calcification (VC) is associated with increased cardiovascular risks in patients with
chronic kidney disease (CKD). Sodium-glucose cotransporter 2 inhibitors, such as …

Empagliflozin Attenuates Vascular Calcification in Mice with Chronic Kidney Disease by Regulating the NFR2/HO-1 Anti-Inflammatory Pathway through AMPK …

L Chia-Wen, L Chung-Jen, YJ Hsieh… - International Journal of …, 2023 - search.proquest.com
Vascular calcification (VC) is associated with increased cardiovascular risks in patients with
chronic kidney disease (CKD). Sodium-glucose cotransporter 2 inhibitors, such as …

Empagliflozin Attenuates Vascular Calcification in Mice with Chronic Kidney Disease by Regulating the NFR2/HO-1 Anti-Inflammatory Pathway through AMPK …

CW Lu, CJ Lee, YJ Hsieh… - International Journal of …, 2023 - search.ebscohost.com
Vascular calcification (VC) is associated with increased cardiovascular risks in patients with
chronic kidney disease (CKD). Sodium-glucose cotransporter 2 inhibitors, such as …

Empagliflozin Attenuates Vascular Calcification in Mice with Chronic Kidney Disease by Regulating the NFR2/HO-1 Anti-Inflammatory Pathway through AMPK …

C Lu, C Lee, Y Hsieh, B Hsu - 2023 - europepmc.org
Vascular calcification (VC) is associated with increased cardiovascular risks in patients with
chronic kidney disease (CKD). Sodium-glucose cotransporter 2 inhibitors, like empagliflozin …